IMMULAB - A Phase II Trial of Immunotherapy With Pembrolizumab in Combination With Local Ablation for Patients With Early Stage Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms IMMULAB
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 02 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 04 Dec 2018 New trial record